Information Provided By:
Fly News Breaks for April 6, 2017
CARA
Apr 6, 2017 | 07:32 EDT
Piper Jaffray analyst Charles Duncan raised his price target for Cara Therapeutics to $27 saying the company's increased cash position reduces the risk to fund "significant "Phase III progress in uremic pruritus and postop pain into the second half of 2019. The analyst sees a buying opportunity and current share levels and keeps an Overweight rating on Cara shares.
News For CARA From the Last 2 Days
There are no results for your query CARA
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.